NICE (UK) positive for Onswik for treating type 2 diabetes – Eli Lilly
Insulin efsitora alfa can be used, within its marketing authorisation, as an option to treat type 2 diabetes in adults. Use the least expensive option of the suitable… read more.
Insulin efsitora alfa can be used, within its marketing authorisation, as an option to treat type 2 diabetes in adults. Use the least expensive option of the suitable… read more.
AnaptysBio, Inc. a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, announced that GSK has received U.S…. read more.
Actinium Pharmaceuticals, Inc. , a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced encouraging initial clinical results from the first‑in‑human Phase 1… read more.
Valneva SE announced that, following a further benefit-risk assessment of Ixchiq for travelers by the United Kingdom’s (UK) Commission on Human Medicines (CHM), the UK marketing authorization for… read more.
Palisade Bio, Inc. a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases, announced clinical and translational findings presented in one oral presentation and three moderated posters at… read more.
Roche announced that the FDA has approved Enspryng (satralizumab) for the treatment of adults with thyroid eye disease (TED), providing patients with the first and only at-home subcutaneous… read more.
Idorsia shared positive findings from two new analyses of the pivotal Phase 3 PRECISION study of aprocitentan in patients with resistant hypertension, at the American Heart Association Hypertension… read more.
Nirogacestat can be used, within its marketing authorisation, as an option to treat progressing desmoid tumours that need systemic treatment in adults. Nirogacestat can only be used if… read more.
Scholar Rock announced it has resubmitted the Marketing Authorisation Application (MAA) for apitegromab for the treatment of children and adults with spinal muscular atrophy (SMA) to the European… read more.
Biofrontera announced that it has submitted a supplemental New Drug Application (sNDA) to the FDA to expand the indication for Ameluz (aminolevulinic acid hydrochloride) topical gel, 10%, in… read more.
Atara Biotherapeutics, Inc. announced that its partner, Pierre Fabre Pharmaceuticals, Inc. (PFP), has received acceptance by the FDA of the Biologics License Application (BLA) resubmission for tabelecleucel, with… read more.
Guardant Health announced that Guardant360 CDx has received CE-marking under Europe’s in Vitro Diagnostic Medical Devices Regulation as a companion diagnostic (CDx) to identify patients with estrogen receptor… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.